Systematic Comparison of the Effects of Alpha-synuclein Mutations on Its Oligomerization and Aggregation

PLoS Genetics

Volumn 10, Issue 11, 2014, Pages

  Lázaro, Diana F ^a   Rodrigues, Eva F ^a   Langohr, Ramona ^b   Shahpasandzadeh, Hedieh ^c   Ribeiro, Thales ^d   Guerreiro, Patrícia ^a,e   Gerhardt, Ellen ^a   Kröhnert, Katharina ^a   Klucken, Jochen ^f   Pereira, Marcos D ^d   Popova, Blagovesta ^c   Kruse, Niels ^a   Mollenhauer, Brit ^a,g   Rizzoli, Silvio O ^a   Braus, Gerhard H ^c   Danzer, Karin M ^b   Outeiro, Tiago F ^a,d  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^g Paracelsus Elena Klinik Kassel   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; LACTATE DEHYDROGENASE; LYSINE;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DEGRADATION; ENDOPLASMIC RETICULUM STRESS; ENZYME RELEASE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE MUTATION; GENETIC TRANSFECTION; GLIOMA CELL; GOLGI COMPLEX; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LYSOSOME; MUTANT; NONHUMAN; OLIGOMERIZATION; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; TOXICITY; WESTERN BLOTTING; YEAST CELL; CELL LINE; GENETICS; LEWY BODY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; POINT MUTATION; PROTEINOSIS; SITE DIRECTED MUTAGENESIS;

ALPHA-SYNUCLEIN; CELL LINE; HUMANS; LEWY BODIES; LYSOSOMES; MUTAGENESIS, SITE-DIRECTED; PARKINSON DISEASE; PHOSPHORYLATION; POINT MUTATION; PROTEIN AGGREGATION, PATHOLOGICAL;

EID: 84912083676     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1004741     Document Type: Article

References (67)

1. Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, et al. (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329: 1663–1667.
2. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839–840.
3. Goedert M, Spillantini MG, Del Tredici K, Braak H, (2013) 100 years of Lewy pathology. Nat Rev Neurol 9: 13–24.
4. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, et al. (1997) Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 62: 10–15.
5. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045–2047.
6. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106–108.
7. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55: 164–173.
8. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841.
9. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364: 1167–1169.
10. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, et al. (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364: 1169–1171.
11. Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, et al. (2004) Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 55: 174–179.
12. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41: 1308–1312.
13. Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, et al. (2011) Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 377: 641–649.
14. Kiely AP, Asi YT, Kara E, Limousin P, Ling H, et al. (2013) alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol 125: 753–769.
15. Lesage S, Anheim M, Letournel F, Bousset L, Honore A, et al. (2013) G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol 73: 459–471.
16. Proukakis C, Dudzik CG, Brier T, MacKay DS, Cooper JM, et al. (2013) A novel alpha-synuclein missense mutation in Parkinson disease. Neurology 80: 1062–1064.
17. Khalaf O, Fauvet B, Oueslati A, Dikiy I, Mahul-Mellier AL, et al. (2014) The H50Q mutation enhances alpha-synuclein aggregation, secretion and toxicity. J Biol Chem 289: 21856–21876.
18. Marques O, Outeiro TF, (2012) Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis 3: e350.
19. Lashuel HA, Overk CR, Oueslati A, Masliah E, (2013) The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14: 38–48.
20. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, et al. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 97: 571–576.
21. Fredenburg RA, Rospigliosi C, Meray RK, Kessler JC, Lashuel HA, et al. (2007) The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry 46: 7107–7118.
22. Goncalves S, Outeiro TF, (2013) Assessing the Subcellular Dynamics of Alpha-synuclein Using Photoactivation Microscopy. Mol Neurobiol 47: 1081–1092.
23. Outeiro TF, Lindquist S, (2003) Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302: 1772–1775.
24. Cai H, Reinisch K, Ferro-Novick S, (2007) Coats, tethers, Rabs, and SNAREs work together to mediate the intracellular destination of a transport vesicle. Dev Cell 12: 671–682.
25. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM, (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20: 3214–3220.
26. Klucken J, Poehler AM, Ebrahimi-Fakhari D, Schneider J, Nuber S, et al. (2012) Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. Autophagy 8: 754–766.
27. Hernandez-Vargas R, Fonseca-Ornelas L, Lopez-Gonzalez I, Riesgo-Escovar J, Zurita M, et al. (2011) Synphilin suppresses alpha-synuclein neurotoxicity in a Parkinson's disease Drosophila model. Genesis 49: 392–402.
28. Bonini NM, Giasson BI, (2005) Snaring the function of alpha-synuclein. Cell 123: 359–361.
29. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L, (2011) Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol 10: 1015–1025.
30. McDowell K, Chesselet MF, (2012) Animal models of the non-motor features of Parkinson's disease. Neurobiol Dis 46: 597–606.
31. Low K, Aebischer P, (2012) Use of viral vectors to create animal models for Parkinson's disease. Neurobiol Dis 48: 189–201.
32. Bezard E, Przedborski S, (2011) A tale on animal models of Parkinson's disease. Mov Disord 26: 993–1002.
33. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, et al. (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4: 160–164.
34. Okochi M, Walter J, Koyama A, Nakajo S, Baba M, et al. (2000) Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J Biol Chem 275: 390–397.
35. Paleologou KE, Schmid AW, Rospigliosi CC, Kim HY, Lamberto GR, et al. (2008) Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem 283: 16895–16905.
36. Taschenberger G, Garrido M, Tereshchenko Y, Bahr M, Zweckstetter M, et al. (2012) Aggregation of alphaSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol 123: 671–683.
37. Dorval V, Fraser PE, (2006) Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. J Biol Chem 281: 9919–9924.
38. Krumova P, Meulmeester E, Garrido M, Tirard M, Hsiao HH, et al. (2011) Sumoylation inhibits alpha-synuclein aggregation and toxicity. J Cell Biol 194: 49–60.
39. Shults CW, (2006) Lewy bodies. Proc Natl Acad Sci U S A 103: 1661–1668.
40. Karpinar DP, Balija MB, Kugler S, Opazo F, Rezaei-Ghaleh N, et al. (2009) Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J 28: 3256–3268.
41. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, et al. (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 108: 4194–4199.
42. Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, et al. (2008) Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS ONE 3: e1867.
43. McLean PJ, Kawamata H, Hyman BT, (2001) Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience 104: 901–912.
44. Tenreiro S, Munder MC, Alberti S, Outeiro TF, (2013) Harnessing the power of yeast to unravel the molecular basis of neurodegeneration. J Neurochem 127: 438–452.
45. Lee HJ, Lee SJ, (2002) Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J Biol Chem 277: 48976–48983.
46. Danzer KM, Ruf WP, Putcha P, Joyner D, Hashimoto T, et al. (2011) Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J 25: 326–336.
47. Remy I, Michnick SW, (2006) A highly sensitive protein-protein interaction assay based on Gaussia luciferase. Nat Methods 3: 977–979.
48. Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, et al. (2000) Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 287: 65–67.
49. El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, et al. (2003) Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 17: 1945–1947.
50. Kruse N, Schulz-Schaeffer WJ, Schlossmacher MG, Mollenhauer B, (2012) Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of alpha-synuclein and other proteins in cerebrospinal fluid. Methods 56: 514–518.
51. Gonatas NK, Stieber A, Gonatas JO, (2006) Fragmentation of the Golgi apparatus in neurodegenerative diseases and cell death. J Neurol Sci 246: 21–30.
52. Fan J, Hu Z, Zeng L, Lu W, Tang X, et al. (2008) Golgi apparatus and neurodegenerative diseases. Int J Dev Neurosci 26: 523–534.
53. Fujita Y, Ohama E, Takatama M, Al-Sarraj S, Okamoto K, (2006) Fragmentation of Golgi apparatus of nigral neurons with alpha-synuclein-positive inclusions in patients with Parkinson's disease. Acta Neuropathol 112: 261–265.
54. Holtz WA, O'Malley KL, (2003) Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. J Biol Chem 278: 19367–19377.
55. Hetz C, (2012) The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol 13: 89–102.
56. Chen L, Feany MB, (2005) Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8: 657–663.
57. Pandey N, Schmidt RE, Galvin JE, (2006) The alpha-synuclein mutation E46K promotes aggregation in cultured cells. Exp Neurol 197: 515–520.
58. Fares MB, Ait-Bouziad N, Dikiy I, Mbefo MK, Jovicic A, et al. (2014) The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of alpha-synuclein, and enhances its secretion and nuclear localization in cells. Hum Mol Genet 23: 4491–4509.
59. Rutherford NJ, Moore BD, Golde TE, Giasson BI (2014) Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of alpha-synuclein. J Neurochem. E-pub ahead of print. doi:10.1111/jnc.12806
60. Trexler AJ, Rhoades E, (2010) Single molecule characterization of alpha-synuclein in aggregation-prone states. Biophys J 99: 3048–3055.
61. Chen L, Periquet M, Wang X, Negro A, McLean PJ, et al. (2009) Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest 119: 3257–3265.
62. Oueslati A, Paleologou KE, Schneider BL, Aebischer P, Lashuel HA, (2012) Mimicking phosphorylation at serine 87 inhibits the aggregation of human alpha-synuclein and protects against its toxicity in a rat model of Parkinson's disease. J Neurosci 32: 1536–1544.
63. Paleologou KE, Oueslati A, Shakked G, Rospigliosi CC, Kim HY, et al. (2010) Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci 30: 3184–3198.
64. El-Agnaf OM, Jakes R, Curran MD, Middleton D, Ingenito R, et al. (1998) Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett 440: 71–75.
65. Hejjaoui M, Butterfield S, Fauvet B, Vercruysse F, Cui J, et al. (2012) Elucidating the role of C-terminal post-translational modifications using protein semisynthesis strategies: alpha-synuclein phosphorylation at tyrosine 125. J Am Chem Soc 134: 5196–5210.
66. Gosavi N, Lee HJ, Lee JS, Patel S, Lee SJ, (2002) Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J Biol Chem 277: 48984–48992.
67. Petroi D, Popova B, Taheri-Talesh N, Irniger S, Shahpasandzadeh H, et al. (2012) Aggregate clearance of alpha-synuclein in S. cerevisiae depends more on autophagosome and vacuole function than on the proteasome. J Biol Chem 287: 27567–27579.